"Discussion
Here, we characterized 88 patients who developed GBS [Guillain-Barré syndrome] following the administration of the COVID-19 vaccine. The majority of cases occurred after receiving a vector-based vaccine with the AZV [Oxford-AstraZeneca] vaccine being the most reported. The motor deficit was the most common finding among patients who received the AZV vaccine. The latency between vaccination and the onset of neurological symptoms was... 2–30 days... The severity of the complications ranged from mild symptoms to severe life-threatening conditions. Thirteen patients required mechanical ventilation. While the favorable outcome was achieved in most cases, some patients had partial recovery and poor outcomes such as unconsciousness and prolonged mechanical ventilation via tracheostomy. A favorable prognosis with a high chance of response to IVIG therapy was in line with our own experience, i.e., we recently reported three cases of post-COVID-19 vaccination GBS of acute motor axonal neuropathy subtype with a considerable short-term recovery in response to treatment with IVIG suggestive for a temporal association between GBS incidence and COVID-19 vaccination..."
https://pmc.ncbi.nlm.nih.gov/articles/PMC9469827/
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.